Tempus licenses neurological patient dataset to Pathos AI in five-year agreement
Tempus AI is licensing a de-identified longitudinal neurological-conditions dataset to Pathos AI and Bristol Myers Squibb for $55 million over five years, extending its oncology data infrastructure into Alzheimer's and dementia. The licence sits alongside a parallel direct Tempus-BMS oncology data and models licence worth up to $137.5 million over five years, and a BMS-led $237 million Series E into Pathos at roughly $3 billion post-money that gave BMS three-year exclusive rights to Pathos's Foundry platform in neuroscience.
Where the rake sits
Tempus holds the substrate and does the enrichment itself (curation of the de-identified multimodal records, Lens, the models), and keeps the licence fees in full: up to $137.5 million from BMS directly and $55 million from BMS/Pathos, inside a disclosed greater than $550 million YTD bookings line. The fees are fixed over five years and do not track what BMS or Pathos learn downstream, so whether the price captures the value extracted (which drug programmes Pathos acquires, which trials BMS designs, Foundry's hypothesis generation and asset selection) is not observable to Tempus from the source. The rake is owned rather than on loan, but it is a fixed-fee rake pointed at buyer decisions worth multiples of the licence.
What happened
- 2026-10-23: Pathos AI announced a five-year, $55 million agreement to license a de-identified longitudinal neurological-conditions dataset that Tempus AI will build from hundreds of thousands of patients, extending the infrastructure Tempus built in oncology.
- 2026-10-23: Pathos said it will run its agentic AI platform Foundry over the dataset to generate hypotheses on disease biology and inform clinical-trial design.
- 2026-10-23: Bristol Myers Squibb led Pathos's $237 million Series E at a post-money valuation of approximately $3 billion, taking three-year exclusive rights to Pathos Foundry in neuroscience and non-exclusive access across its broader R&D portfolio.
- 2026-10: In parallel, Tempus entered a strategic collaboration with BMS directly licensing oncology data and models to BMS for up to $137.5 million over a five-year term.
- 2026-11-02: Tempus AI reported Q3 2026 total revenue of $411.5 million, up 23% year on year, with Data and Applications revenue of $108.1 million, up 33%, and Insights up 29%.
- 2026-11-02: Tempus reported oncology volume growth of 32% and MRD test volume of approximately 12,000 in the quarter, up 300% year on year.
- 2026-11-02: Tempus disclosed year-to-date data-licensing bookings greater than $550 million after the October BMS collaboration, scoping the $55 million BMS/Pathos licence as covering patients with Alzheimer's or dementia.
- 2026-11-02: Tempus raised full-year 2026 revenue guidance to $1.60 to $1.605 billion and reiterated full-year Adjusted EBITDA of approximately $65 million.
Who is involved
Tempus does genome sequencing and precision medicine, including diagnostics, primarily for cancer patients.
Pathos AI is an AI and technology company developing drugs.
The reading
Tempus builds and curates the de-identified longitudinal neuro dataset; the enrichment on it - hypothesis generation, disease-biology analysis and trial design - is done by Pathos using its Foundry platform, with BMS also getting access via a side-letter arrangement.
The substrate is a specialised longitudinal cohort in Alzheimer's and other neurological conditions; what makes it worth $55m to Pathos is the buyer's decision Foundry has to make - which clinical asset to acquire and how to design its trials, now extended into neuroscience under BMS's three-year exclusive.
A de-identified neurology dataset and record updates crossed to Pathos (and, via the side letter, into use with BMS); patient identities, Tempus's broader oncology corpus and Tempus's own models did not.
Not determinable; the fee is fixed and Pathos's valuation jumped to about $3bn in the same week, but the public facts do not establish whether $55m priced the extracted value correctly.
Why it matters
This is intricate. BMS is paying (via Pathos) $55 million for a dataset Tempus has not yet built, and $137.5 million for oncology data and models direct, while separately writing a $237 million cheque that marks Pathos at $3 billion and locks Foundry to BMS in neuroscience for three years. Tempus owns the enrichment and keeps the fees, but the fixed five-year price is pointed at drug-selection decisions whose value accrues to Pathos's equity and BMS's pipeline, neither of which Tempus observes.
The argument this deal tests: The identifier on loan
Related deals
- Tempus expands multi-year Merck collaboration giving Merck access to de-identified multimodal data and Lens platform2026-03-03
- Owkin licenses K Pro AI Scientist plus multimodal oncology and immunology patient data to Boehringer Ingelheim2026-09-02
- TriNetX licenses access to data on about 300 million patients to Regeneron for drug discovery2026-04-02
- Tempus AI expands multi-year collaboration giving Gilead enterprise-wide access to Lens platform and multimodal real-world oncology data2026-04-09
Sources
- pathos.com — primary
- markets.chroniclejournal.com — corroborating
- tempus.com — party background
- tikr.com — party background
- siliconangle.com — party background
- fiercebiotech.com — party background
Announced 2026-10-23